CY1120573T1 - Παραγωγα πυριδαζινης για χρηση στην προληψη ή θεραπεια αταξικης διαταραχης - Google Patents

Παραγωγα πυριδαζινης για χρηση στην προληψη ή θεραπεια αταξικης διαταραχης

Info

Publication number
CY1120573T1
CY1120573T1 CY20181100843T CY181100843T CY1120573T1 CY 1120573 T1 CY1120573 T1 CY 1120573T1 CY 20181100843 T CY20181100843 T CY 20181100843T CY 181100843 T CY181100843 T CY 181100843T CY 1120573 T1 CY1120573 T1 CY 1120573T1
Authority
CY
Cyprus
Prior art keywords
prevention
pyridazine
classical
products
disorder treatment
Prior art date
Application number
CY20181100843T
Other languages
Greek (el)
English (en)
Inventor
Sarah Almond
Original Assignee
Takeda Pharmaceutical Company Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50554599&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1120573(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical Company Limited filed Critical Takeda Pharmaceutical Company Limited
Publication of CY1120573T1 publication Critical patent/CY1120573T1/el

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/501Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CY20181100843T 2014-03-06 2018-08-10 Παραγωγα πυριδαζινης για χρηση στην προληψη ή θεραπεια αταξικης διαταραχης CY1120573T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1403944.0A GB201403944D0 (en) 2014-03-06 2014-03-06 New use
PCT/GB2015/050654 WO2015132608A1 (en) 2014-03-06 2015-03-06 Pyridazine derivatives for use in the prevention or treatment of an ataxic disorder

Publications (1)

Publication Number Publication Date
CY1120573T1 true CY1120573T1 (el) 2019-07-10

Family

ID=50554599

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20181100843T CY1120573T1 (el) 2014-03-06 2018-08-10 Παραγωγα πυριδαζινης για χρηση στην προληψη ή θεραπεια αταξικης διαταραχης

Country Status (32)

Country Link
US (1) US20170014407A1 (enExample)
EP (1) EP3113778B1 (enExample)
JP (1) JP6510549B2 (enExample)
KR (1) KR20160126081A (enExample)
CN (1) CN106102743A (enExample)
AU (1) AU2015225954B2 (enExample)
CA (1) CA2940342A1 (enExample)
CL (1) CL2016002151A1 (enExample)
CY (1) CY1120573T1 (enExample)
DK (1) DK3113778T3 (enExample)
EA (1) EA036438B1 (enExample)
ES (1) ES2676905T3 (enExample)
GB (1) GB201403944D0 (enExample)
GE (1) GEP20196984B (enExample)
HR (1) HRP20181082T1 (enExample)
IL (1) IL247435A0 (enExample)
LT (1) LT3113778T (enExample)
MA (1) MA39315A1 (enExample)
MX (1) MX2016010524A (enExample)
MY (1) MY202127A (enExample)
PH (1) PH12016501751A1 (enExample)
PL (1) PL3113778T3 (enExample)
PT (1) PT3113778T (enExample)
RS (1) RS57594B1 (enExample)
SG (1) SG11201607106YA (enExample)
SI (1) SI3113778T1 (enExample)
SM (1) SMT201800367T1 (enExample)
TR (1) TR201809537T4 (enExample)
TW (1) TW201534591A (enExample)
UA (1) UA123352C2 (enExample)
WO (1) WO2015132608A1 (enExample)
ZA (1) ZA201604611B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3115B1 (ar) 2011-08-22 2017-09-20 Takeda Pharmaceuticals Co مركبات بيريدازينون واستخدامها كمثبطات daao
GB201222711D0 (en) 2012-12-17 2013-01-30 Takeda Pharmaceutical Novel compounds
US10118917B2 (en) 2014-04-29 2018-11-06 E I Du Pont De Nemours And Company Pyridazinone herbicides
TWI785022B (zh) 2017-03-28 2022-12-01 美商富曼西公司 新穎噠嗪酮類除草劑
US11213030B2 (en) 2017-06-30 2022-01-04 Fmc Corporation 4-(3,4-dihydronaphth-1-yl or 2H-chromen-4-yl)-5-hydroxy-2H-pyradizin-3-ones as herbicides
CN112569217B (zh) * 2019-09-30 2022-04-22 厦门大学 戊酸衍生物在治疗遗传性小脑共济失调中的应用
JP2021138648A (ja) 2020-03-04 2021-09-16 武田薬品工業株式会社 経口固形製剤
CA3209781A1 (en) 2021-03-01 2022-09-09 Takeda Pharmaceuticals Company Limited Use of luvadaxistat for the treatment of cognitive impairment

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE321553T1 (de) * 1998-06-10 2006-04-15 Meiji Seika Kaisha Arzneimittel für hinterstrangataxie und zusammensetzung zur behandlung von hinterstrangataxie
WO2003047558A2 (en) * 2001-12-03 2003-06-12 Genset S.A. Treatment of cns disorders using d-amino acid oxidase and d-aspartate oxidase inhibitors
JO3115B1 (ar) * 2011-08-22 2017-09-20 Takeda Pharmaceuticals Co مركبات بيريدازينون واستخدامها كمثبطات daao

Also Published As

Publication number Publication date
CA2940342A1 (en) 2015-09-11
EA036438B1 (ru) 2020-11-11
SMT201800367T1 (it) 2018-09-13
GB201403944D0 (en) 2014-04-23
JP6510549B2 (ja) 2019-05-08
MA39315A1 (fr) 2017-09-29
AU2015225954B2 (en) 2020-06-18
RS57594B1 (sr) 2018-11-30
SG11201607106YA (en) 2016-09-29
TW201534591A (zh) 2015-09-16
PL3113778T3 (pl) 2018-11-30
KR20160126081A (ko) 2016-11-01
DK3113778T3 (en) 2018-07-30
JP2017507156A (ja) 2017-03-16
TR201809537T4 (tr) 2018-07-23
EP3113778B1 (en) 2018-06-06
ES2676905T3 (es) 2018-07-26
LT3113778T (lt) 2018-08-27
AU2015225954A1 (en) 2016-07-07
GEP20196984B (en) 2019-06-25
MX2016010524A (es) 2016-10-31
CN106102743A (zh) 2016-11-09
SI3113778T1 (en) 2018-08-31
CL2016002151A1 (es) 2016-12-30
EA201691566A1 (ru) 2016-12-30
PH12016501751A1 (en) 2017-02-06
MY202127A (en) 2024-04-05
UA123352C2 (uk) 2021-03-24
IL247435A0 (en) 2016-11-30
PT3113778T (pt) 2018-07-11
WO2015132608A1 (en) 2015-09-11
ZA201604611B (en) 2017-09-27
EP3113778A1 (en) 2017-01-11
HRP20181082T1 (hr) 2018-09-07
US20170014407A1 (en) 2017-01-19

Similar Documents

Publication Publication Date Title
CY1120573T1 (el) Παραγωγα πυριδαζινης για χρηση στην προληψη ή θεραπεια αταξικης διαταραχης
CY1122255T1 (el) Ενωσεις ν-((ετ)αρυλμεθυλ)-ετεροαρυλ-καρβοξαμιδιων ως αναστολεις καλλικρεϊνης πλασματος
ECSP17073743A (es) Moduladores de k-ras
MX394380B (es) Compuestos dinucleótidos cíclicos para eltratamiento de cáncer
CY1121534T1 (el) Ενωσεις διυδροβενζοφουρανιου χρησιμες στην αγωγη του διαβητη και της παχυσαρκιας
CY1123592T1 (el) Αναστολεας κινασης aurora a
UY34750A (es) ?compuestos para el tratamiento del hiv, composiciones,métodos de preparación, intermediarios y métodos terapéuticos?.
CY1121554T1 (el) Παραγωγο πυρανοχρωμενυλ-φαινολης, και φαρμακευτικη συνθεση για αγωγη μεταβολικου συνδρομου ή φλεγμονωδους παθησης
CL2016002072A1 (es) 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer
CL2016003422A1 (es) Inhibidores de demetilasa-1 específico de lisina
TR201813877T4 (tr) Spi̇nal müsküler atrofi̇ni̇n tedavi̇ edi̇lmesi̇ne yöneli̇k bi̇leşi̇kler.
MX2016012574A (es) Compuestos heteroarilo sustituidos y metodos de uso.
CL2016003423A1 (es) Inhibidores de demetilasa-1 específico de lisina
EA201790627A1 (ru) СТИМУЛЯТОРЫ рГЦ
HRP20181490T1 (hr) Spojevi 1, 3, 4-tiadiazola i njihova upotreba u liječenju raka
EA201691412A1 (ru) Гидроксиформамидные производные и их применение
DOP2016000297A (es) Composiciones farmacéuticas útiles para tratar enfermedades infecciosas
CY1120700T1 (el) Ενωσεις τριαμινοπυριμιδινης χρησιμες για προληψη ή αγωγη ελονοσιας
CY1119532T1 (el) (s)-πιρλινδολη και τα φαρμακευτικως αποδεκτα αλατα αυτης για χρηση στην ιατρικη
MX382092B (es) Compuestos heterocíclicos para el tratamiento de enfermedades.
EA201790687A1 (ru) Хинолинкарбоксамиды для применения в лечении множественной миеломы
JOP20190163B1 (ar) منشط nrf2
BR112017020374A2 (pt) compostos bicíclicos fundidos para o tratamento de doença
ZA201802399B (en) Aminothiolester compounds or pharmaceutically acceptable salts thereof, for use in the treatment of cancer
PH12016502480A1 (en) Compounds, pharmaceutical composition and their use in treating neurodegenerative diseases